Director Jane Gross (ATYR) awarded 50,000 aTyr Pharma stock options at $0.95

Rhea-AI Filing Summary

aTyr Pharma director Jane A. Gross received a grant of stock options covering 50,000 shares of Common Stock. The options have an exercise price of $0.95 per share and were awarded at no upfront cost as a compensation grant.

The options vest in full on the earlier of May 11, 2027 or the company’s 2027 Annual Meeting of Stockholders, as long as Gross continues to serve on the Board. After this grant, she holds 50,000 stock options directly according to the filing.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Gross Jane A

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	50,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 50,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Stock options granted: 50,000 options Exercise price: $0.95 per share Underlying shares: 50,000 shares +2 more

5 metrics

Stock options granted 50,000 options Grant to director Jane A. Gross on May 11, 2026

Exercise price $0.95 per share Strike price of stock option grant

Underlying shares 50,000 shares Common Stock underlying the options

Options held after grant 50,000 options Total derivative holdings following transaction

Option expiration May 11, 2036 Expiration date of stock options

Key Terms

Stock Option (right to buy), non-employee director compensation policy, vests in full, Annual Meeting of Stockholders

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

non-employee director compensation policy financial

"The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full"

vests in full financial

"The option ... vests in full on the earlier of (i) May 11, 2027 or (ii) the Issuer's 2027 Annual Meeting"

Annual Meeting of Stockholders regulatory

"the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gross Jane A

(Last) (First) (Middle)

C/O ATYR PHARMA, INC.

10240 SORRENTO VALLEY ROAD, SUITE 300

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
aTYR PHARMA INC [ ATYR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.95	05/11/2026		A		50,000		(1)	05/11/2036	Common Stock	50,000	$0.00	50,000	D

Explanation of Responses:

1. The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 11, 2027 or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors.

	/s/ Nancy E. Denyes, as Attorney-in-Fact	05/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did aTyr Pharma (ATYR) director Jane A. Gross report on this Form 4?

Jane A. Gross reported receiving a grant of stock options for 50,000 shares. These options are part of non-employee director compensation and give her the right to buy aTyr Pharma common stock at a fixed exercise price of $0.95 per share.

How many aTyr Pharma (ATYR) shares are covered by the new stock options?

The new stock option grant covers 50,000 shares of aTyr Pharma common stock. This entire amount was reported as acquired in a single transaction, and 50,000 options are shown as held following the transaction in the Form 4.

What is the exercise price of Jane A. Gross’s aTyr Pharma (ATYR) stock options?

The exercise price of the stock options is $0.95 per share. This means Gross can purchase aTyr Pharma common stock at $0.95 for each of the 50,000 option shares once the options are vested and exercisable.

When do Jane A. Gross’s aTyr Pharma (ATYR) stock options vest?

The options vest in full on the earlier of May 11, 2027 or the company’s 2027 Annual Meeting of Stockholders. Vesting is conditioned on her continued service on aTyr Pharma’s Board of Directors through that vesting date.

Is this aTyr Pharma (ATYR) Form 4 a market purchase or a compensation grant?

This Form 4 reflects a compensation-related grant, not a market purchase. The transaction code “A” and footnote indicate the options were granted under the non-employee director compensation policy as a grant or award acquisition.